Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.
Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in developed countries, and the rates of NAFLD continue to rise in conjunction with the obesity pandemic. While the majority of patients with isolated steatosis generally have a benign course, a diagnosis of nonalcoho...
| Publicado en: | Gastroenterology & Hepatology Vol. 12; no. 12; pp. 756 - 764 |
|---|---|
| Autores principales: | , , |
| Formato: | tables/charts Journal Article |
| Publicado: |
Gastro-Hep Communications, Inc
Dec2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120180558&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 120180558 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15547914 6N5B jtl: Gastroenterology & Hepatology issn: 15547914 maglogo: N pubinfo: dt: Dec2016 vid: 12 iid: 12 pid: 72163 pub: Gastro-Hep Communications, Inc place: New York, New York artinfo: ui: 120180558 120180558 120180558 120180558 ppf: 756 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials. aug: au: Hannah Jr., William N. Torres, Dawn M. Harrison, Stephen A. affil: Associate professor at the Uniformed Services University of the Health Sciences in Bethesda, Maryland sug: subj: Nonalcoholic Fatty Liver Disease Liver Diseases Nonalcoholic Fatty Liver Disease Epidemiology Weight Loss Developed Countries ab: Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in developed countries, and the rates of NAFLD continue to rise in conjunction with the obesity pandemic. While the majority of patients with isolated steatosis generally have a benign course, a diagnosis of nonalcoholic steatohepatitis (NASH) carries a significantly higher risk for progression of disease, cirrhosis, and death. Pharmacologic therapeutic interventions in NASH have largely proven to be ineffective or unappealing due to long-term side-effect profiles, and the majority of patients cannot achieve or sustain targeted weight loss goals, necessitating an urgent need for therapeutic trials and drug development. The complex molecular mechanisms leading to NASH and the long duration of time to develop complications of disease are challenges to developing meaningful clinical endpoints. Because of these challenges, surrogate endpoints that are linked to all-cause mortality, liver-related death, and complications of cirrhosis are much more likely to be beneficial in the majority of patients. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|